The EMA’s Committee for Medicinal Products for Human Use has recommended marketing authorization for prasterone for the treatment of postmenopausal women with vulvar and vaginal atrophy.
International Approvals …read more
The EMA’s Committee for Medicinal Products for Human Use has recommended marketing authorization for prasterone for the treatment of postmenopausal women with vulvar and vaginal atrophy.
International Approvals …read more